You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 120 No. 11, November 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Clinical Sciences
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on ISI (6)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Glaucoma
 •Prostheses/ Implants
 •Alert me on articles by topic

Intracameral Tissue Plasminogen Activator Use in a Large Series of Eyes With Valved Glaucoma Drainage Implants

Alan H. Zalta, MD; Charles P. Sweeney, MD; Alyson K. Zalta; Adam H. Kaufman, MD

Arch Ophthalmol. 2002;120:1487-1493.

Objective  To describe the efficacy and complications of intracameral tissue plasminogen activator (tPA) in a large series of glaucomatous eyes with valved glaucoma drainage implants (GDIs).

Methods  A retrospective analysis of 620 Ahmed and Krupin aqueous shunts implanted between December 1992 and May 2001 identified 36 eyes treated with intracameral tPA for total or imminent tube obstruction by fibrin and/or blood. For a successful ocular outcome, tPA use must prevent the need for additional glaucoma surgery to replace or revise an occluded drainage implant.

Results  Intracameral tPA successfully cleared or prevented tube occlusion by fibrin/blood clots in 32 (88.9%) of 36 eyes. Multiple tPA injections were administered in 38.9% of eyes, and the mean number of injections required to achieve successful outcomes was 1.6. The mean ± SD tPA dose per injection was 9.8 ± 3.1 µg, and the mean ± SD total tPA dose required to achieve successful outcomes was 15.5 ± 9.9 µg. For injections to be successful in totally occluded tubes (n = 31), the mean ± SD intraocular pressure change 24 hours after tPA administration was –21.2 ± 15.6 mm Hg. Significant complications, including severe hyphema, profound hypotony, and anterior chamber flattening, occurred after 10.9% of tPA administrations.

Conclusion  Intracameral tPA clears and prevents obstruction of valved GDIs by fibrin and/or blood clots.


From the Department of Ophthalmology, University of Cincinnati College of Medicine, Cincinnati, Ohio (Drs Zalta and Kaufman); Cincinnati Eye Institute, Cincinnati (Drs Zalta and Kaufman); Department of the Army, Brooke Army Medical Center, Fort Sam Houston, Tex (Dr Sweeney); and Harvard College, Cambridge, Mass (Ms Zalta).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Silicone Oil Pupillary Block: An Exception to Combined Argon-Nd:YAG Laser Iridotomy Success in Angle-closure Glaucoma
Zalta et al.
Arch Ophthalmol 2007;125:883-888.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.